ROS and brain diseases: The good, the bad, and the ugly

Oxidative Medicine and Cellular Longevity

Volumn , Issue , 2013, Pages

  Popa Wagner, Aurel ^a   Mitran, Smaranda ^b   Sivanesan, Senthilkumar ^c   Chang, Edwin ^d   Buga, Ana Maria ^a,b  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b UNIVERSITY OF MEDICINE AND PHARMACY OF CRAIOVA   (Romania)

^c IOWA STATE UNIVERSITY   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; REACTIVE OXYGEN METABOLITE;

ANIMAL; BRAIN DISEASE; HUMAN; METABOLISM; MITOCHONDRION; OXIDATIVE STRESS; PATHOLOGY; REVIEW;

ANIMALS; BIOLOGICAL MARKERS; BRAIN DISEASES; HUMANS; MITOCHONDRIA; OXIDATIVE STRESS; PPAR GAMMA; REACTIVE OXYGEN SPECIES;

EID: 84893859296     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2013/963520     Document Type: Review

References (183)

1. Dole M., The natural history of oxygen. The Journal of General Physiology 1965 49 1 5 27 2-s2.0-0013802107
2. Campbell N. A., Reece J. B., Biology 2005 7th Pearson-Benjamin Cummings
3. Rich P. R., The molecular machinery of Keilin's respiratory chain. Biochemical Society Transactions 2003 31 6 1095 1105 2-s2.0-0347419305 (Pubitemid 38030918)
4. Guglielmotto M., Tamagno E., Danni O., Oxidative stress and hypoxia contribute to Alzheimer's disease pathogenesis: two sides of the same coin. TheScientificWorldJournal 2009 9 1 781 791 2-s2.0-70350767274 10.1100/tsw.2009.93
5. Chen S.-D., Yang D.-I., Lin T.-K., Shaw F.-Z., Liou C.-W., Chuang Y.-C., Roles of oxidative stress, apoptosis, PGC-1 and mitochondrial biogenesis in cerebral ischemia. International Journal of Molecular Sciences 2011 12 10 7199 7215 2-s2.0-80055029604 10.3390/ijms12107199
6. Valko M., Leibfritz D., Moncol J., Cronin M. T. D., Mazur M., Telser J., Free radicals and antioxidants in normal physiological functions and human disease. International Journal of Biochemistry and Cell Biology 2007 39 1 44 84 2-s2.0-33749986298 10.1016/j.biocel.2006.07.001 (Pubitemid 44566469)
7. Michel T. M., Pülschen D., Thome J., The role of oxidative stress in depressive disorders. Current Pharmaceutical Design 2012 18 36 5890 5899
8. Wang X., Zhao X., Contribution of oxidative damage to antimicrobial lethality. Antimicrobial Agents and Chemotherapy 2009 53 4 1395 1402 2-s2.0-65649104513 10.1128/AAC.01087-08
9. Dröge W., Free radicals in the physiological control of cell function. Physiological Reviews 2002 82 1 47 95 2-s2.0-0036086130 (Pubitemid 34654215)
10. Lu S.-P., Lin Feng M.-H., Huang H.-L., Huang Y.-C., Tsou W.-I., Lai M.-Z., Reactive oxygen species promote raft formation in T lymphocytes. Free Radical Biology & Medicine 2007 42 7 936 944 2-s2.0-33847684721 10.1016/j.freeradbiomed.2006.11.027 (Pubitemid 46356887)
11. Atkins C. M., Sweatt J. D., Reactive oxygen species mediate activity-dependent neuron-glia signaling in output fibers of the hippocampus. The Journal of Neuroscience 1999 19 17 7241 7248 2-s2.0-0033198188 (Pubitemid 29404580)
12. Hu D., Serrano F., Oury T. D., Klann E., Aging-dependent alterations in synaptic plasticity and memory in mice that overexpress extracellular superoxide dismutase. The Journal of Neuroscience 2006 26 15 3933 3941 2-s2.0-33646101468 10.1523/JNEUROSCI.5566-05.2006 (Pubitemid 44315413)
13. Mehta S. L., Kumari S., Mendelev N., Li P. A., Selenium preserves mitochondrial function, stimulates mitochondrial biogenesis, and reduces infarct volume after focal cerebral ischemia. BMC Neuroscience 2012 13, article 79 10.1186/1471-2202-13-79
14. Badjatia N., Seres D., Carpenter A., Schmidt J. M., Lee K., Mayer S. A., Claassen J., Connolly E. S., Elkind M. S., Free fatty acids and delayed cerebral ischemia after subarachnoid hemorrhage. Stroke 2012 43 3 691 696 2-s2.0-84857654580 10.1161/STROKEAHA.111.636035
15. Chen G., Jing C. H., Liu P. P., Ruan D., Wang L., Induction of autophagic cell death in the rat brain caused by iron. The American Journal of the Medical Sciences 2013 345 5 369 374 10.1097/MAJ.0b013e318271c031
16. McCracken E., Valeriani V., Simpson C., Jover T., McCulloch J., Dewar D., The lipid peroxidation by-product 4-hydroxynonenal is toxic to axons and oligodendrocytes. Journal of Cerebral Blood Flow and Metabolism 2000 20 11 1529 1536 2-s2.0-0033756824
17. Cui J., Holmes E. H., Greene T. G., Liu P. K., Oxidative DNA damage precedes DNA fragmentation after experimental stroke in rat brain. FASEB Journal 2000 14 7 955 967 2-s2.0-0034014316 (Pubitemid 30241673)
18. Panov A., Dikalov S., Shalbuyeva N., Hemendinger R., Greenamyre J. T., Rosenfeld J., Species- and tissue-specific relationships between mitochondrial permeability transition and generation of ROS in brain and liver mitochondria of rats and mice. American Journal of Physiology-Cell Physiology 2007 292 2 C708 C718 2-s2.0-33847041066 10.1152/ajpcell.00202.2006
19. Hansson M. J., Månsson R., Morota S., Uchino H., Kallur T., Sumi T., Ishii N., Shimazu M., Keep M. F., Jegorov A., Elmér E., Calcium-induced generation of reactive oxygen species in brain mitochondria is mediated by permeability transition. Free Radical Biology & Medicine 2008 45 3 284 294 2-s2.0-46449116985 10.1016/j.freeradbiomed.2008.04.021
20. Opii W. O., Nukala V. N., Sultana R., Pandya J. D., Day K. M., Merchant M. L., Klein J. B., Sullivan P. G., Butterfield D. A., Proteomic identification of oxidized mitochondrial proteins following experimental traumatic brain injury. Journal of Neurotrauma 2007 24 5 772 789 2-s2.0-34249096439 10.1089/neu.2006.0229 (Pubitemid 46799270)
21. Lemasters J. J., Theruvath T. P., Zhong Z., Nieminen A.-L., Mitochondrial calcium and the permeability transition in cell death. Biochimica et Biophysica Acta 2009 1787 11 1395 1401 2-s2.0-68649095201 10.1016/j.bbabio.2009.06.009
22. Rasola A., Sciacovelli M., Pantic B., Bernardi P., Signal transduction to the permeability transition pore. FEBS Letters 2010 584 10 1989 1996 2-s2.0-77952671613 10.1016/j.febslet.2010.02.022
23. Halliwell B., Oxidative stress and neurodegeneration: where are we now? Journal of Neurochemistry 2006 97 6 1634 1658 2-s2.0-33745013111 10.1111/j.1471-4159.2006.03907.x (Pubitemid 43873658)
24. Tobe E. H., Mitochondrial dysfunction, oxidative stress, and major depressive disorder. Neuropsychiatric Disease and Treatment 2013 9 567 573
25. Tsaluchidu S., Cocchi M., Tonello L., Puri B. K., Fatty acids and oxidative stress in psychiatric disorders. BMC Psychiatry 2008 8 supplement 1, article S5 2-s2.0-46949102135 10.1186/1471-244X-8-S1-S5 (Pubitemid 351964890)
26. Masood A., Nadeem A., Mustafa S. J., O'Donnell J. M., Reversal of oxidative stress-induced anxiety by inhibition of phosphodiesterase-2 in mice. Journal of Pharmacology and Experimental Therapeutics 2008 326 2 369 379 2-s2.0-47949118698 10.1124/jpet.108.137208
27. Arranz M. J., de Leon J., Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Molecular Psychiatry 2007 12 8 707 747 2-s2.0-34547469943 10.1038/sj.mp.4002009 (Pubitemid 47172693)
28. Bouayed J., Rammal H., Younos C., Soulimani R., Positive correlation between peripheral blood granulocyte oxidative status and level of anxiety in mice. European Journal of Pharmacology 2007 564 1-3 146 149 2-s2.0-34250787612 10.1016/j.ejphar.2007.02.055 (Pubitemid 46957515)
29. Bouayed J., Rammal H., Soulimani R., Oxidative stress and anxiety Relationship and cellular pathways. Oxidative Medicine and Cellular Longevity 2009 2 2 63 72 2-s2.0-63449091380
30. Marazziti D., Baroni S., Picchetti M., Landi P., Silvestri S., Vatteroni E., Catena Dell'Osso M., Psychiatric disorders and mitochondrial dysfunctions. European Review for Medical and Pharmacological Sciences 2012 16 2 270 275 2-s2.0-84859482117
31. Hovatta I., Juhila J., Donner J., Oxidative stress in anxiety and comorbid disorders. Neuroscience Research 2010 68 4 261 275 2-s2.0-78149470797 10.1016/j.neures.2010.08.007
32. Ng F., Berk M., Dean O., Bush A. I., Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. International Journal of Neuropsychopharmacology 2008 11 6 851 876 2-s2.0-50849139232 10.1017/S1461145707008401
33. Auerbach B. D., Osterweil E. K., Bear M. F., Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 2011 480 7375 63 68 2-s2.0-82555196668 10.1038/nature10658
34. Ben-David E., Shifman S., Networks of neuronal genes affected by common and rare variants in autism spectrum disorders. PLoS Genetics 2012 8 3 2-s2.0-84859241496 10.1371/journal.pgen.1002556 e1002556
35. Dagda R. K., Cherra S. J. III, Kulich S. M., Tandon A., Park D., Chu C. T., Loss of PINK1 function promotes mitophagy through effects on oxidative stress and mitochondrial fission. The Journal of Biological Chemistry 2009 284 20 13843 13855 2-s2.0-67649399288 10.1074/jbc.M808515200
36. Boess F. G., Hendrix M., van der Staay F.-J., Erb C., Schreiber R., Van Staveren W., De Vente J., Prickaerts J., Blokland A., Koenig G., Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004 47 7 1081 1092 2-s2.0-8844220521 10.1016/j.neuropharm.2004.07.040 (Pubitemid 39535847)
37. Werner C., Raivich G., Cowen M., Strekalova T., Sillaber I., Buters J. T., Spanagel R., Hofmann F., Importance of NO/cGMP signalling via cGMP-dependent protein kinase II for controlling emotionality and neurobehavioural effects of alcohol. European Journal of Neuroscience 2004 20 12 3498 3506 2-s2.0-10944220561 10.1111/j.1460-9568.2004.03793.x (Pubitemid 40013559)
38. Wang X., Pinto-Duarte A., Sejnowski T. J., Behrens M. M., How Nox2-containing NADPH oxidase affects cortical circuits in the NMDA receptor antagonist model of schizophrenia. Antioxidants & Redox Signaling 2013 18 12 1444 1462
39. Rossignol D. A., Frye R. E., A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Molecular Psychiatry 2012 17 4 389 401 2-s2.0-84859005372 10.1038/mp.2011.165
40. Gu F., Chauhan V., Kaur K., Brown W. T., Lafauci G., Wegiel J., Chauhan A., Alterations in mitochondrial DNA copy number and the activities of electron transport chain complexes and pyruvate dehydrogenase in the frontal cortex from subjects with autism. Translational Psychiatry 2013 3, article e299 10.1038/tp.2013.68
41. Johnson A. W., Jaaro-Peled H., Shahani N., Sedlak T. W., Zoubovsky S., Burruss D., Emiliani F., Sawa A., Gallagher M., Cognitive and motivational deficits together with prefrontal oxidative stress in a mouse model for neuropsychiatric illness. Proceedings of the National Academy of Sciences of the United States of America 2013 110 30 12462 12467
42. Kano S., Colantuoni C., Han F., Zhou Z., Yuan Q., Wilson A., Takayanagi Y., Lee Y., Rapoport J., Eaton W., Cascella N., Ji H., Goldman D., Sawa A., Genome-wide profiling of multiple histone methylations in olfactory cells: further implications for cellular susceptibility to oxidative stress in schizophrenia. Molecular Psychiatry 2012 18 7 740 742
43. Kubera M., Grygier B., Wrona D., Rogóz Z., Roman A., Basta-Kaim A., Budziszewska B., Leskiewicz M., Jantas D., Nowak W., Maes M., Lason W., Stimulatory effect of antidepressant drug pretreatment on progression of B16F10 melanoma in high-active male and female C57BL/6J mice. Journal of Neuroimmunology 2011 240-241 34 44 2-s2.0-83555176364 10.1016/j.jneuroim.2011. 09.006
44. Maes M., Fišar Z., Medina M., Scapagnini G., Nowak G., Berk M., New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates-Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology 2012 20 3 127 150
45. Wang X., Lo E. H., Triggers and mediators of hemorrhagic transformation in cerebral ischemia. Molecular Neurobiology 2003 28 3 229 244 2-s2.0-0742321910 10.1385/MN:28:3:229 (Pubitemid 38156421)
46. Godínez-Rubí M., Rojas-Mayorquín A. E., Ortuño-Sahagún D., Nitric oxide donors as neuroprotective agents after an ischemic stroke-related inflammatory reaction. Oxidative Medicine and Cellular Longevity 2013 2013 16 297357 10.1155/2013/297357
47. Love S., Oxidative stress in brain ischemia. Brain Pathology 1999 9 1 119 131 2-s2.0-0032924640 (Pubitemid 29056523)
48. Lakhan S. E., Kirchgessner A., Hofer M., Inflammatory mechanisms in ischemic stroke: therapeutic approaches. Journal of Translational Medicine 2009 7, article 97 2-s2.0-71049180369 10.1186/1479-5876-7-97
49. del Zoppo G. J., Hallenbeck J. M., Advances in the vascular pathophysiology of ischemic stroke. Thrombosis Research 2000 98 3 V73 V81 2-s2.0-0034192486 (Pubitemid 30254137)
50. Harari O. A., Liao J. K., NF- B and innate immunity in ischemic stroke. Annals of the New York Academy of Sciences 2010 1207 32 40 2-s2.0-78149259667 10.1111/j.1749-6632.2010.05735.x
51. Nichols T. C., NF- B and reperfusion injury. Drug News & Perspectives 2004 17 2 99 104 2-s2.0-2342519916 10.1358/dnp.2004.17.2.829042 (Pubitemid 38568406)
52. Wei Z., Chigurupati S., Arumugam T. V., Jo D.-G., Li H., Chan S. L., Notch activation enhances the microglia-mediated inflammatory response associated with focal cerebral ischemia. Stroke 2011 42 9 2589 2594 2-s2.0-80052424570 10.1161/STROKEAHA.111.614834
53. Pradillo J. M., Fernández-López D., García- Yébenes I., Sobrado M., Hurtado O., Moro M. A., Lizasoain I., Toll-like receptor 4 is involved in neuroprotection afforded by ischemic preconditioning. Journal of Neurochemistry 2009 109 1 287 294 2-s2.0-61849108779 10.1111/j.1471-4159.2009.05972.x
54. Caso J. R., Pradillo J. M., Hurtado O., Lorenzo P., Moro M. A., Lizasoain I., Toll-like receptor 4 is involved in brain damage and inflammation after experimental stroke. Circulation 2007 115 12 1599 1608 2-s2.0-34247545017 10.1161/CIRCULATIONAHA.106.603431 (Pubitemid 46648645)
55. Caso J. R., Pradillo J. M., Hurtado O., Leza J. C., Moro M. A., Lizasoain I., Toll-like receptor 4 is involved in subacute stress-induced neuroinflammation and in the worsening of experimental stroke. Stroke 2008 39 4 1314 1320 2-s2.0-41149112041 10.1161/STROKEAHA.107.498212 (Pubitemid 351440707)
56. Gill R., Tsung A., Billiar T., Linking oxidative stress to inflammation: toll-like receptors. Free Radical Biology & Medicine 2010 48 9 1121 1132 2-s2.0-77950338003 10.1016/j.freeradbiomed.2010.01.006
57. Suzuki Y., Hattori K., Hamanaka J., Murase T., Egashira Y., Mishiro K., Ishiguro M., Tsuruma K., Hirose Y., Tanaka H., Yoshimura S., Shimazawa M., Inagaki N., Nagasawa H., Iwama T., Hara H., Pharmacological inhibition of TLR4-NOX4 signal protects against neuronal death in transient focal ischemia. Surface Science Reports 2012 2, article 896
58. Jenner P., Olanow C. W., The pathogenesis of cell death in Parkinson's disease. Neurology 2006 66 10, supplement 4 S24 S36 2-s2.0-33744977254
59. Hirsch E. C., Hunot S., Neuroinflammation in Parkinson's disease: a target for neuroprotection? The Lancet Neurology 2009 8 4 382 397 2-s2.0-62549133546 10.1016/S1474-4422(09)70062-6
60. Gallagher D. A., Schapira A. H. V., Etiopathogenesis and treatment of Parkinson's disease. Current Topics in Medicinal Chemistry 2009 9 10 860 868 2-s2.0-74249119940 10.2174/156802609789378227
61. Wu D.-C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., Przedborski S., NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2003 100 10 6145 6150 2-s2.0-0037947448 10.1073/pnas.0937239100 (Pubitemid 36576945)
62. Blum-Degena D., Müller T., Kuhn W., Gerlach M., Przuntek H., Riederer P., Interleukin-1 β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neuroscience Letters 1995 202 1-2 17 20 2-s2.0-0029417080 10.1016/0304-3940(95) 12192-7
63. González-Scarano F., Baltuch G., Microglia as mediators of inflammatory and degenerative diseases. Annual Review of Neuroscience 1999 22 219 240 2-s2.0-0032942060 10.1146/annurev.neuro.22.1.219 (Pubitemid 29144887)
64. Pabon M. M., Bachstetter A. D., Hudson C. E., Gemma C., Bickford P. C., CX3CL1 reduces neurotoxicity and microglial activation in a rat model of Parkinson's disease. Journal of Neuroinflammation 2011 8, article 9 2-s2.0-78951475702 10.1186/1742-2094-8-9
65. Joglar B., Rodriguez-Pallares J., Rodriguez-Perez A. I., Rey P., Guerra M. J., Labandeira-Garcia J. L., The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease. Journal of Neurochemistry 2009 109 2 656 669 2-s2.0-62649089147 10.1111/j.1471-4159.2009.05999.x
66. Reynolds A. D., Stone D. K., Mosley R. L., Gendelman H. E., Nitrated α -synuclein-induced alterations in microglial immunity are regulated by CD4+ T cell subsets. Journal of Immunology 2009 182 7 4137 4149 2-s2.0-64249169415 10.4049/jimmunol.0803982
67. Markesbery W. R., Carney J. M., Oxidative alterations in Alzheimer's disease. Brain Pathology 1999 9 1 133 146 2-s2.0-0032902974 (Pubitemid 29056524)
68. Verri M., Pastoris O., Dossena M., Aquilani R., Guerriero F., Cuzzoni G., Venturini L., Ricevuti G., Bongiorno A. I., Mitochondrial alterations, oxidative stress and neuroinflammation in Alzheimer's disease. International Journal of Immunopathology and Pharmacology 2012 25 2 345 353
69. Leuner K., Müller W. E., Reichert A. S., From mitochondrial dysfunction to amyloid beta formation: novel insights into the pathogenesis of Alzheimer's disease. Molecular Neurobiology 2012 46 1 186 193
70. Younessi P., Yoonessi A., Advanced glycation end-products and their receptor-mediated roles: inflammation and oxidative stress. Iranian Journal of Medical Sciences 2011 36 3 154 166 2-s2.0-80955135583
71. Kalaria R. N., Harshbarger-Kelly M., Cohen D. L., Premkumar D. R. D., Molecular aspects of inflammatory and immune responses in Alzheimer's disease. Neurobiology of Aging 1996 17 5 687 693 2-s2.0-0030250614 10.1016/0197-4580(96) 00114-5 (Pubitemid 26348869)
72. Bornemann K. D., Wiederhold K.-H., Pauli C., Ermini F., Stalder M., Schnell L., Sommer B., Jucker M., Staufenbiel M., A β -induced inflammatory processes in microglia cells of APP23 transgenic mice. American Journal of Pathology 2001 158 1 63 73 2-s2.0-0034746387 (Pubitemid 32096472)
73. Kitazawa M., Yamasaki T. R., LaFerla F. M., Microglia as a potential bridge between the amyloid β -peptide and tau. Annals of the New York Academy of Sciences 2004 1035 85 103 2-s2.0-14944367845 10.1196/annals.1332.006 (Pubitemid 40362328)
74. Cribbs D. H., Berchtold N. C., Perreau V., Coleman P. D., Rogers J., Tenner A. J., Cotman C. W., Extensive innate immune gene activation accompanies brain aging, increasing vulnerability to cognitive decline and neurodegeneration: a microarray study. Journal of Neuroinflammation 2012 9, article 179
75. Zhang W., Wang L.-Z., Yu J.-T., Chi Z.-F., Tan L., Increased expressions of TLR2 and TLR4 on peripheral blood mononuclear cells from patients with Alzheimer's disease. Journal of the Neurological Sciences 2012 315 1-2 67 71 2-s2.0-84858001196 10.1016/j.jns.2011.11.032
76. Jin J.-J., Kim H.-D., Maxwell J. A., Li L., Fukuchi K.-I., Toll-like receptor 4-dependent upregulation of cytokines in a transgenic mouse model of Alzheimer's disease. Journal of Neuroinflammation 2008 5, article 23 2-s2.0-45849105153 10.1186/1742-2094-5-23 (Pubitemid 351877817)
77. Tang S.-C., Lathia J. D., Selvaraj P. K., Jo D.-G., Mughal M. R., Cheng A., Siler D. A., Markesbery W. R., Arumugam T. V., Mattson M. P., Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid β -peptide and the membrane lipid peroxidation product 4-hydroxynonenal. Experimental Neurology 2008 213 1 114 121 2-s2.0-49349097868 10.1016/j.expneurol.2008.05.014
78. Balistreri C. R., Colonna-Romano G., Lio D., Candore G., Caruso C., TLR4 polymorphisms and ageing: Implications for the pathophysiology of age-related diseases. Journal of Clinical Immunology 2009 29 4 406 415 2-s2.0-67651213832 10.1007/s10875-009-9297-5
79. Drechsel D. A., Estévez A. G., Barbeito L., Beckman J. S., Nitric oxide-mediated oxidative damage and the progressive demise of motor neurons in ALS. Neurotoxicity Research 2012 22 4 251 264 2-s2.0-84859415239 10.1007/s12640-012-9322-y
80. Gonsette R. E., Neurodegeneration in multiple sclerosis: the role of oxidative stress and excitotoxicity. Journal of the Neurological Sciences 2008 274 1-2 48 53 2-s2.0-53049093018 10.1016/j.jns.2008.06.029
81. Zeis T., Probst A., Steck A. J., Stadelmann C., Brück W., Schaeren-Wiemers N., Molecular changes in white matter adjacent to an active demyelinating lesion in early multiple sclerosis: molecular changes in MS periplaque white matter. Brain Pathology 2009 19 3 459 466 2-s2.0-66949152122 10.1111/j.1750-3639.2008.00231.x
82. Fischer M. T., Sharma R., Lim J. L., Haider L., Frischer J. M., Drexhage J., Mahad D., Bradl M., Van Horssen J., Lassmann H., NADPH oxidase expression in active multiple sclerosis lesions in relation to oxidative tissue damage and mitochondrial injury. Brain 2012 135 3 886 899 2-s2.0-84857538385 10.1093/brain/aws012
83. Ratanayake U., Quinn T., Walker D. W., Dickinson H., Cytokines and the neurodevelopmental basis of mental illness. Frontiers in Neuroscience 2013 17 7, article 180
84. Meyer U., Nyffeler M., Engler A., Urwyler A., Schedlowski M., Knuesel I., Yee B. K., Feldon J., The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology. The Journal of Neuroscience 2006 26 18 4752 4762 2-s2.0-33646926705 10.1523/JNEUROSCI.0099- 06.2006 (Pubitemid 44315314)
85. Gilmore J. H., Jarskog L. F., Vadlamudi S., Lauder J. M., Prenatal infection and risk for schizophrenia: IL-1 β IL-6, and TNF α inhibit cortical neuron dendrite development. Neuropsychopharmacology 2004 29 7 1221 1229 2-s2.0-2942683385 10.1038/sj.npp.1300446 (Pubitemid 38780645)
86. Chez M. G., Dowling T., Patel P. B., Khanna P., Kominsky M., Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic childre. Pediatric Neurology 2007 36 6 361 365 2-s2.0-34249864530 10.1016/j. pediatrneurol.2007.01.012 (Pubitemid 46873913)
87. Potvin S., Stip E., Sepehry A. A., Gendron A., Bah R., Kouassi E., Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biological Psychiatry 2008 63 8 801 808 2-s2.0-40949107708 10.1016/j.biopsych.2007.09.024 (Pubitemid 351410515)
88. Ashwood P., Krakowiak P., Hertz-Picciotto I., Hansen R., Pessah I., Van de Water J., Elevated plasma cytokines in autism spectrum disorders provide evidence of immune dysfunction and are associated with impaired behavioral outcome. Brain, Behavior, and Immunity 2011 25 1 40 45 2-s2.0-78649322790 10.1016/j.bbi.2010.08.003
89. Bilbo S. D., Schwarz J. M., Early-life programming of later-life brain and behavior: a critical role for the immune system. Frontiers in Behavioral Neuroscience 2009 3, article 14 10.3389/neuro.08.014.2009
90. Bennet L., Gunn A., Wintour-Coghlan M., Owens J., The fetal origins of adult mental illness. Early Life Origins of Health and Disease (Advances in Experimental Medicine and Biology) 2006 New York, NY, USA Springer 204 211 10.1007/0-387-32632-4-17
91. Morgan J. T., Chana G., Pardo C. A., Achim C., Semendeferi K., Buckwalter J., Courchesne E., Everall I. P., Microglial activation and increased microglial density observed in the dorsolateral prefrontal cortex in autism. Biological Psychiatry 2010 68 4 368 376 2-s2.0-77955684004 10.1016/j.biopsych. 2010.05.024
92. Fredericks C. A., Drabant E. M., Edge M. D., Tillie J. M., Hallmayer J., Ramel W., Kuo J. R., Mackey S., Gross J. J., Dhabhar F. S., Healthy young women with serotonin transporter SS polymorphism show a pro-inflammatory bias under resting and stress conditions. Brain, Behavior, and Immunity 2010 24 3 350 357 2-s2.0-77951622489 10.1016/j.bbi.2009.10.014
93. Macchi F., Homberg J. R., Calabrese F., Zecchillo C., Racagni G., Riva M. A., Molteni R., Altered inflammatory responsiveness in serotonin transporter mutant rats. Journal of Neuroinflammation 2013 10, article 116
94. Monji A., Kato T. A., Mizoguchi Y., Horikawa H., Seki Y., Kasai M., Yamauchi Y., Yamada S., Kanba S., Neuroinflammation in schizophrenia especially focused on the role of microglia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2013 42 115 121 2-s2.0-84855590675 10.1016/j.pnpbp.2011. 12.002
95. Liaury K., Miyaoka T., Tsumori T., Furuya M., Wake R., Ieda M., Tsuchie K., Taki M., Ishihara K., Tanra A. J., Horiguchi J., Morphological features of microglial cells in the hippocampal dentate gyrus of Gunn rat: a possible schizophrenia animal model. Journal of Neuroinflammation 2012 9, article 56 2-s2.0-84858260810 10.1186/1742-2094-9-56
96. Post R. M., Kindling and sensitization as models for affective episode recurrence, cyclicity, and tolerance phenomena. Neuroscience and Biobehavioral Reviews 2007 31 6 858 873 2-s2.0-34548016732 10.1016/j.neubiorev.2007.04.003 (Pubitemid 47285350)
97. Berk M., Kapczinski F., Andreazza A. C., Dean O. M., Giorlando F., Maes M., Yücel M., Gama C. S., Dodd S., Dean B., Magalhães P. V. S., Amminger P., McGorry P., Malhi G. S., Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neuroscience and Biobehavioral Reviews 2011 35 3 804 817 2-s2.0-78649938042 10.1016/j.neubiorev.2010.10.001
98. Iyengar R. L., Gandhi S., Aneja A., Thorpe K., Razzouk L., Greenberg J., Mosovich S., Farkouh M. E., NSAIDs are associated with lower depression scores in patients with osteoarthritis. American Journal of Medicine 2013 126 11 1017.e11 1017.e18
99. Harris J. L., Yeh H. W., Choi I. Y., Lee P., Berman N., Swerdlow R., Craciunas S., Brooks W., Altered neurochemical profile after traumatic brain injury: 1H-MRS biomarkers of pathological mechanisms. Journal of Cerebral Blood Flow & Metabolism 2012 32 12 2122 2134
100. Rossignol D. A., Frye R. E., A review of research trends in physiological abnormalities in autism spectrum disorders: immune dysregulation, inflammation, oxidative stress, mitochondrial dysfunction and environmental toxicant exposures. Molecular Psychiatry 2012 17 4 389 401 2-s2.0-84859005372 10.1038/mp.2011.165
101. Ming X., Brimacombe M., Chaaban J., Zimmerman-Bier B., Wagner G. C., Autism spectrum disorders: concurrent clinical disorders. Journal of Child Neurology 2008 23 1 6 13 2-s2.0-37449005152 10.1177/0883073807307102
102. Frye R. E., Delatorre R., Taylor H., Slattery J., Melnyk S., Chowdhury N., James S. J., Redox metabolism abnormalities in autistic children associated with mitochondrial disease. Translational Psychiatry 2013 3, article e273
103. Rose S., Melnyk S., Pavliv O., Bai S., Nick T. G., Frye R. E., James S. J., Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. Translational Psychiatry 2012 10 2, article e134 10.1038/tp.2012.61
104. Kulak A., Steullet P., Cabungcal J. H., Werge T., Ingason A., Cuenod M., Do K. Q., Redox dysregulation in the pathophysiology of schizophrenia and bipolar disorder: insights from animal models. Antioxidants & Redox Signaling 2013 18 12 1428 1443
105. Jorgensen A., Krogh J., Miskowiak K., Bolwig T. G., Kessing L. V., Fink-Jensen A., Nordentoft M., Henriksen T., Weimann A., Poulsen H. E., Jorgensen M. B., Systemic oxidatively generated DNA/RNA damage in clinical depression: associations to symptom severity and response to electroconvulsive therapy. Journal of Affective Disorders 2013 149 1-3 355 362
106. Durand T., De Felice C., Signorini C., Oger C., Bultel-Poncé V., Guy A., Galano J. M., Leoncini S., Ciccoli L., Pecorelli A., Valacchi G., Hayek J., F(2)-Dihomo-isoprostanes and brain white matter damage in stage 1 Rett syndrome. Biochimie 2013 95 86 90
107. Flatow J., Buckley P., Miller B. J., Meta-analysis of oxidative stress in schizophrenia. Biological Psychiatry 2013 74 6 400 409 10.1016/j.biopsych.2013. 03.018
108. Bulut M., Selek S., Gergerlioglu H. S., Savas H. A., Yilmaz H. R., Yuce M., Ekici G., Malondialdehyde levels in adult attention-deficit hyperactivity disorder. Journal of Psychiatry and Neuroscience 2007 32 6 435 438 2-s2.0-37049037510 (Pubitemid 350248231)
109. Dwivedi Y., Rizavi H. S., Conley R. R., Roberts R. C., Tamminga C. A., Pandey G. N., Altered gene expression of brain-derived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Archives of General Psychiatry 2003 60 8 804 815 2-s2.0-0042154427 10.1001/archpsyc.60.8.804 (Pubitemid 36960912)
110. Sklar P., Gabriel S. B., McInnis M. G., Bennett P., Lim Y.-M., Tsan G., Schaffner S., Kirov G., Jones I., Owen M., Craddock N., DePaulo J. R., Lander E. S., Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Molecular Psychiatry 2002 7 6 579 593 2-s2.0-0036347948 10.1038/sj.mp.4001058
111. Sen S., Nesse R. M., Stoltenberg S. F., Li S., Gleiberman L., Chakravarti A., Weder A. B., Burmeister M., A BDNF coding variant is associated with the NEO personality inventory domain neuroticism, a risk factor for depression. Neuropsychopharmacology 2003 28 2 397 401 2-s2.0-0037310231
112. Kaufman J., Yang B.-Z., Douglas-Palumberi H., Grasso D., Lipschitz D., Houshyar S., Krystal J. H., Gelernter J., Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children. Biological Psychiatry 2006 59 8 673 680 2-s2.0-33645337891 10.1016/j.biopsych.2005.10.026
113. Chen Z.-Y., Jing D., Bath K. G., Ieraci A., Khan T., Siao C.-J., Herrera D. G., Toth M., Yang C., McEwen B. S., Hempstead B. L., Lee F. S., Genetic variant BDNF (Val66Met) polymorphism alters anxiety-related behavior. Science 2006 314 5796 140 143 2-s2.0-33749649795 10.1126/science.1129663 (Pubitemid 44547760)
114. Sen S., Duman R., Sanacora G., Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biological Psychiatry 2008 64 6 527 532 2-s2.0-49749101642 10.1016/j.biopsych. 2008.05.005
115. Versace A., Andreazza A. C., Young L. T., Fournier J. C., Almeida J. R. C., Stiffler R. S., Lockovich J. C., Aslam H. A., Pollock M. H., Park H., Nimgaonkar V. L., Kupfer D. J., Phillips M. L., Elevated serum measures of lipid peroxidation and abnormal prefrontal white matter in euthymic bipolar adults: toward peripheral biomarkers of bipolar disorder. Molecular Psychiatry 2013 10.1038/mp.2012.188
116. Najjar S., Pearlman D. M., Hirsch S., Friedman K., Strange J., Reidy J., Khoukaz M., Ferrell R. B., Devinsky O., Najjar A., Zagzag D., Brain biopsy findings link major depressive disorder to neuroinflammation, oxidative stress, and neurovascular dysfunction: a case report. Biological Psychiatry 2013 10.1016/j.biopsych.2013.07.041
117. Kosenko E. A., Aliev G., Tikhonova L. A., Li Y., Poghosyan A. C., Kaminsky Y. G., Antioxidant status and energy state of erythrocytes in Alzheimer dementia: probing for markers. CNS & Neurological Disorders Drug Targets 2012 11 7 926 932
118. Cardoso S. M., Proença M. T., Santos S., Santana I., Oliveira C. R., Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiology of Aging 2004 25 1 105 110 2-s2.0-0348111546 10.1016/S0197-4580(03) 00033-2 (Pubitemid 37522198)
119. Bosetti F., Brizzi F., Barogi S., Mancuso M., Siciliano G., Tendi E. A., Murri L., Rapoport S. I., Solaini G., Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiology of Aging 2002 23 3 371 376 2-s2.0-0036231792 10.1016/S0197-4580(01)00314-1 (Pubitemid 34312019)
120. Mancuso M., Filosto M., Bosetti F., Ceravolo R., Rocchi A., Tognoni G., Manca M. L., Solaini G., Siciliano G., Murri L., Decreased platelet cytochrome c oxidase activity is accompanied by increased blood lactate concentration during exercise in patients with Alzheimer disease. Experimental Neurology 2003 182 2 421 426 2-s2.0-0043166643 10.1016/S0014-4886(03)00092-X (Pubitemid 36937094)
121. Leuner K., Schulz K., Schütt T., Pantel J., Prvulovic D., Rhein V., Savaskan E., Czech C., Eckert A., Müller W. E., Peripheral mitochondrial dysfunction in Alzheimer's disease: focus on lymphocytes. Molecular Neurobiology 2012 46 1 194 204
122. Puertas M. C., Martínez-Martos J. M., Cobo M. P., Carrera M. P., Mayas M. D., Ramírez-Expósito M. J., Plasma oxidative stress parameters in men and women with early stage Alzheimer type dementia. Experimental Gerontology 2012 47 8 625 630
123. Okun E., Arumugam T. V., Tang S.-C., Gleichmann M., Albeck M., Sredni B., Mattson M. P., The organotellurium compound ammonium trichloro(dioxoethylene-0, 0′) tellurate enhances neuronal survival and improves functional outcome in an ischemic stroke model in mice. Journal of Neurochemistry 2007 102 4 1232 1241 2-s2.0-34547404713 10.1111/j.1471-4159.2007.04615.x (Pubitemid 47174227)
124. Nagotani S., Hayashi T., Sato K., Zhang W., Deguchi K., Nagano I., Shoji M., Abe K., Reduction of cerebral infarction in stroke-prone spontaneously hypertensive rats by statins associated with amelioration of oxidative stress. Stroke 2005 36 3 670 672 2-s2.0-14844328997 10.1161/01.STR.0000155732.27333.3c (Pubitemid 40344176)
125. Lee W. C., Wong H. Y., Chai Y. Y., Shi C. W., Amino N., Kikuchi S., Huang S. H., Lipid peroxidation dysregulation in ischemic stroke: plasma 4-HNE as a potential biomarker? Biochemical and Biophysical Research Communications 2012 425 4 842 847
126. Selley M. L., (E)-4-Hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radical Biology & Medicine 1998 25 2 169 174 2-s2.0-0032527641 10.1016/S0891-5849(98)00021-5 (Pubitemid 28293150)
127. Ilic T. V., Jovanovic M., Jovicic A., Tomovic M., Oxidative stress indicators are elevated in de novo Parkinson's disease patients. Functional Neurology 1999 14 3 141 147 2-s2.0-0032786731
128. Bulut M., Selek S., Bez Y., Cemal Kaya M., Gunes M., Karababa F., Celik H., Asuman Savas H., Lipid peroxidation markers in adult attention deficit hyperactivity disorder: new findings for oxidative stress. Psychiatry Research 2013 209 3 638 642
129. Akyol Ö., Herken H., Uz E., Fadilliolu E., Ünal S., Söüt S., Özyurt H., Savaş H. A., The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients: the possible role of oxidant/antioxidant imbalance. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2002 26 5 995 1005 2-s2.0-0036592438 10.1016/S0278-5846(02)00220-8 (Pubitemid 35245568)
130. Ceylan M., Sener S., Bayraktar A. C., Kavutcu M., Oxidative imbalance in child and adolescent patients with attention-deficit/hyperactivity disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2010 34 8 1491 1494 2-s2.0-78649523256 10.1016/j.pnpbp.2010.08.010
131. Sanders L. H., Timothy Greenamyre J., Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. Free Radical Biology & Medicine 2013 62 111 120
132. Gulec M., Ozkol H., Selvi Y., Tuluce Y., Aydin A., Besiroglu L., Ozdemir P. G., Oxidative stress in patients with primary insomnia. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2012 37 2 247 251 2-s2.0-84859591503 10.1016/j.pnpbp.2012.02.011
133. Kalra J., Rajput A. H., Mantha S. V., Chaudhary A. K., Prasad K., Oxygen free radical producing activity of polymorphonuclear leukocytes in patients with Parkinson's disease. Molecular and Cellular Biochemistry 1992 112 2 181 186 2-s2.0-0026728880
134. Cristalli D. O., Arnal N., Marra F. A., de Alaniz M. J. T., Marra C. A., Peripheral markers in neurodegenerative patients and their first-degree relatives. Journal of the Neurological Sciences 2012 314 1-2 48 56 2-s2.0-84857037658 10.1016/j.jns.2011.11.001
135. Kouti L., Noroozian M., Akhondzadeh S., Abdollahi M., Javadi M. R., Faramarzi M. A., Mousavi S., Ghaeli P., Nitric oxide and peroxynitrite serum levels in Parkinson's disease: correlation of oxidative stress and the severity of the disease. European Review for Medical and Pharmacological Sciences 2013 17 7 964 970
136. Haxaire C., Turpin F. R., Potier B., Kervern M., Sinet P.-M., Barbanel G., Mothet J.-P., Dutar P., Billard J.-M., Reversal of age-related oxidative stress prevents hippocampal synaptic plasticity deficits by protecting d-serine-dependent NMDA receptor activation. Aging Cell 2012 11 2 336 344 2-s2.0-84858342905 10.1111/j.1474-9726.2012.00792.x
137. Qin L., Liu Y., Hong J. S., Crews F. T., NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration. Glia 2013 61 6 855 868
138. Milani P., Ambrosi G., Gammoh O., Blandini F., Cereda C., SOD1 and DJ-1 converge at Nrf2 pathway: a clue for antioxidant therapeutic potential in neurodegeneration. Oxidative Medicine and Cellular Longevity 2013 2013 12 836760 10.1155/2013/836760
139. Cheng M. Y., Lee I.-P., Jin M., Sun G., Zhao H., Steinberg G. K., Sapolsky R. M., An insult-inducible vector system activated by hypoxia and oxidative stress for neuronal gene therapy. Translational Stroke Research 2011 2 1 92 100 2-s2.0-79951517175 10.1007/s12975-010-0060-2
140. Li Y., Paonessa J. D., Zhang Y., Mechanism of chemical activation of Nrf2. PLoS One 2012 7 4 e35122
141. Gan L., Vargas M. R., Johnson D. A., Johnson J. A., Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model. The Journal of Neuroscience 2012 32 49 17775 17787
142. Son T. G., Kawamoto E. M., Yu Q. S., Greig N. H., Mattson M. P., Camandola S., Naphthazarin protects against glutamate-induced neuronal death via activation of the Nrf2/ARE pathway. Biochemical and Biophysical Research Communications 2013 433 4 602 606
143. Dinkova-Kostova A. T., Holtzclaw W. D., Cole R. N., Itoh K., Wakabayashi N., Katoh Y., Yamamoto M., Talalay P., Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proceedings of the National Academy of Sciences of the United States of America 2002 99 18 11908 11913 2-s2.0-0037015035 10.1073/pnas.172398899 (Pubitemid 34994497)
144. Hong F., Freeman M. L., Liebler D. C., Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane. Chemical Research in Toxicology 2005 18 12 1917 1926 2-s2.0-29644443964 10.1021/tx0502138 (Pubitemid 43023050)
145. Jiang H., Tian X., Guo Y., Duan W., Bu H., Li C., Activation of nuclear factor erythroid 2-related factor 2 cytoprotective signaling by curcumin protect primary spinal cord astrocytes against oxidative toxicity. Biological and Pharmaceutical Bulletin 2011 34 8 1194 1197 2-s2.0-80051500260 10.1248/bpb.34.1194
146. Kaidery N. A., Banerjee R., Yang L., Smirnova N. A., Hushpulian D. M., Liby K. T., Williams C. R., Yamamoto M., Kensler T. W., Ratan R. R., Sporn M. B., Beal M. F., Gazaryan I. G., Thomas B., Targeting Nrf2-mediated gene transcription by extremely potent synthetic triterpenoids attenuate dopaminergic neurotoxicity in the MPTP mouse model of Parkinson's disease. Antioxidants & Redox Signaling 2013 18 2 139 157 10.1089/ars.2011.4491
147. L'Episcopo F., Tirolo C., Testa N., Caniglia S., Morale M. C., Impagnatiello F., Pluchino S., Marchetti B., Aging-induced Nrf2-ARE pathway disruption in the subventricular zone drives neurogenic impairment in Parkinsonian mice via PI3K-Wnt/ β -Catenin dysregulation. The Journal of Neuroscience 2013 33 4 1462 1485
148. Pérez-de-Puig I., Martín A., Gorina R., de la Rosa X., Martinez E., Planas A. M., Induction of hemeoxygenase-1 expression after inhibition of hemeoxygenase activity promotes inflammation and worsens ischemic brain damage in mice. Neuroscience 2013 243 22 32
149. Buga A. M., Scholz C. J., Kumar S., Herndon J. G., Alexandru D., Cojocaru G. R., Dandekar T., Popa-Wagner A., Identification of new therapeutic targets by genome-wide analysis of gene expression in the ipsilateral cortex of aged rats after stroke. PLoS One 2012 7 e50985
150. Bousquet M., Calon F., Cicchetti F., Impact of omega-3 fatty acids in Parkinson's disease. Ageing Research Reviews 2011 10 4 453 463 2-s2.0-80052340822 10.1016/j.arr.2011.03.001
151. Joshi K., Lad S., Kale M., Patwardhan B., Mahadik S. P., Patni B., Chaudhary A., Bhave S., Pandit A., Supplementation with flax oil and vitamin C improves the outcome of Attention Deficit Hyperactivity Disorder (ADHD). Prostaglandins Leukotrienes and Essential Fatty Acids 2006 74 1 17 21 2-s2.0-28844450287 10.1016/j.plefa.2005.10.001 (Pubitemid 41773064)
152. Richardson A. J., Montgomery P., The Oxford-Durham Study: a randomized, controlled trial of dietary supplementation with fatty acids in children with developmental coordination disorder. Pediatrics 2005 115 5 1360 1366 2-s2.0-20744445534 10.1542/peds.2004-2164 (Pubitemid 43843244)
153. Kamat C. D., Gadal S., Mhatre M., Williamson K. S., Pye Q. N., Hensley K., Antioxidants in central nervous system diseases: preclinical promise and translational challenges. Journal of Alzheimer's Disease 2008 15 3 473 493 2-s2.0-57349180534
154. Bjelakovic G., Nikolova D., Gluud L. L., Simonetti R. G., Gluud C., Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. The Journal of the American Medical Association 2007 297 8 842 857 2-s2.0-33847378451 10.1001/jama.297.8.842 (Pubitemid 46333949)
155. Høyer-Hansen M., Nordbrandt S. P. S., Jäättelä M., Autophagy as a basis for the health-promoting effects of vitamin D. Trends in Molecular Medicine 2010 16 7 295 302
156. Tuohimaa P., Keisala T., Minasyan A., Cachat J., Kalueff A., Vitamin D, nervous system and aging. Psychoneuroendocrinology 2009 34 1 S278 S286 2-s2.0-71249144773 10.1016/j.psyneuen.2009.07.003
157. Kaundal R. K., Sharma S. S., Peroxisome proliferator-activated receptor γ agonists as neuroprotective agents. Drug News & Perspectives 2010 23 4 241 256 2-s2.0-77954589341 10.1358/dnp.2010.23.4.1437710
158. Polvani S., Tarocchi M., Galli A., PPAR and oxidative stress: Con(β) catenating NRF2 and FOXO. PPAR Research 2012 2012 15 2-s2.0-84859762514 10.1155/2012/641087 641087
159. Haraguchi T., Iwasaki K., Takasaki K., Uchida K., Naito T., Nogami A., Kubota K., Shindo T., Uchida N., Katsurabayashi S., Mishima K., Nishimura R., Fujiwara M., Telmisartan, a partial agonist of peroxisome proliferator-activated receptor γ improves impairment of spatial memory and hippocampal apoptosis in rats treated with repeated cerebral ischemia. Brain Research 2010 1353 1 125 132 2-s2.0-77956393248 10.1016/j.brainres.2010.07.017
160. Washida K., Ihara M., Nishio K., Fujita Y., Maki T., Yamada M., Takahashi J., Wu X., Kihara T., Ito H., Tomimoto H., Takahashi R., Nonhypotensive dose of telmisartan attenuates cognitive impairment partially due to peroxisome proliferator-activated receptor- γ activation in mice with chronic cerebral hypoperfusion. Stroke 2010 41 8 1798 1806 2-s2.0-77955171963 10.1161/STROKEAHA.110.583948
161. Kishi T., Hirooka Y., Sunagawa K., Telmisartan protects against cognitive decline via up-regulation of brain-derived neurotrophic factor/tropomyosin- related kinase B in hippocampus of hypertensive rats. Journal of Cardiology 2012 60 6 489 494
162. Xu F., Li J., Ni W., Shen Y. W., Zhang X. P., Peroxisome proliferator-activated receptor- γ agonist 15d-prostaglandin J2 mediates neuronal autophagy after cerebral ischemia-reperfusion injury. PLoS One 2013 8 1 e55080
163. Tureyen K., Kapadia R., Bowen K. K., Satriotomo I., Liang J., Feinstein D. L., Vemuganti R., Peroxisome proliferator-activated receptor- γ agonists induce neuroprotection following transient focal ischemia in normotensive, normoglycemic as well as hypertensive and type-2 diabetic rodents. Journal of Neurochemistry 2007 101 1 41 56 2-s2.0-33947204503 10.1111/j.1471-4159.2006.04376.x (Pubitemid 46426485)
164. Park S.-W., Yi J.-H., Miranpuri G., Satriotomo I., Bowen K., Resnick D. K., Vemuganti R., Thiazolidinedione class of peroxisome proliferator-activated receptor γ agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats. Journal of Pharmacology and Experimental Therapeutics 2007 320 3 1002 1012 2-s2.0-33847093475 10.1124/jpet.106.113472 (Pubitemid 46294061)
165. Pereira M. P., Hurtado O., Cárdenas A., Alonso-Escolano D., Boscá L., Vivancos J., Nombela F., Leza J. C., Lorenzo P., Lizasoain I., Moro M. A., The nonthiazolidinedione PPAR γ agonist L-796,449 is neuroprotective in experimental stroke. Journal of Neuropathology and Experimental Neurology 2005 64 9 797 805 2-s2.0-24644503529 (Pubitemid 41285813)
166. Chungpaibulpatana J., Sumpatanarax T., Thadakul N., Chantharatreerat C., Konkaew M., Aroonlimsawas M., Hyperbaric oxygen therapy in Thai autistic children. Journal of the Medical Association of Thailand 2008 91 8 1232 1238 2-s2.0-50949097997
167. Rossignol D. A., Rossignol L. W., Hyperbaric oxygen therapy may improve symptoms in autistic children. Medical Hypotheses 2006 67 2 216 228 2-s2.0-33744739160 10.1016/j.mehy.2006.02.009 (Pubitemid 43825617)
168. Joseph C., Buga A. M., Vintilescu R., Balseanu A. T., Moldovan M., Junker H., Walker L., Lotze M., Popa-Wagner, Prolonged gaseous hypothermia prevents the upregulation of phagocytosis-specific protein annexin 1 and causes low-amplitude EEG activity in the aged rat brain after cerebral ischemia. Journal of Cerebral Blood Flow & Metabolism 2012 32 8 1632 1642
169. Ji Q., Hui K., Zhang L., Sun X., Li W., Duan M., The effect of hydrogen-rich saline on the brain of rats with transient ischemia. Journal of Surgical Research 2011 168 1 e95 e101 2-s2.0-79955607676 10.1016/j.jss.2011.01. 057
170. Li J., Dong Y., Chen H., Han H., Yu Y., Wang G., Zeng Y., Xie K., Protective effects of hydrogen-rich saline in a rat model of permanent focal cerebral ischemia via reducing oxidative stress and inflammatory cytokines. Brain Research 2012 1486 1 103 111
171. Khairova R., Pawar R., Salvadore G., Juruena M. F., De Sousa R. T., Soeiro-De-Souza M. G., Salvador M., Zarate C. A., Gattaz W. F., Machado-Vieira R., Effects of lithium on oxidative stress parameters in healthy subjects. Molecular Medicine Reports 2012 5 3 680 682 2-s2.0-84856243953 10.3892/mmr.2011.732
172. Chuang D. M., Wang Z., Chiu C. T., GSK-3 as a target for lithium-induced neuroprotection against excitotoxicity in neuronal cultures and animal models of ischemic stroke. Frontiers in Molecular Neuroscience 2011 4, article 15 10.3389/fnmol.2011.00015
173. Pignitter M., Gorren A. C. F., Nedeianu S., Schmidt K., Mayer B., Inefficient spin trapping of superoxide in the presence of nitric-oxide: implications for studies on nitric-oxide synthase uncoupling. Free Radical Biology & Medicine 2006 41 3 455 463 2-s2.0-33745907851 10.1016/j. freeradbiomed.2006.04.004 (Pubitemid 44041054)
174. Talarowska M., Gałecki P., Maes M., Orzechowska A., Chamielec M., Bartosz G., Kowalczyk E., Nitric oxide plasma concentration associated with cognitive impairment in patients with recurrent depressive disorder. Neuroscience Letters 2012 510 2 127 131 2-s2.0-84856772767 10.1016/j.neulet. 2012.01.018
175. Yoshitomi T., Hirayama A., Nagasaki Y., The ROS scavenging and renal protective effects of pH-responsive nitroxide radical-containing nanoparticles. Biomaterials 2011 32 31 8021 8028 2-s2.0-80051815640 10.1016/j.biomaterials. 2011.07.014
176. Michel T. M., Sheldrick A. J., Camara S., Grnblatt E., Schneider F., Riederer P., Alteration of the pro-oxidant xanthine oxidase (XO) in the thalamus and occipital cortex of patients with schizophrenia. World Journal of Biological Psychiatry 2011 12 8 588 597 2-s2.0-82955246786 10.3109/15622975. 2010.526146
177. Hu X., Zhou H., Zhang D., Yang S., Qian L., Wu H. M., Chen P. S., Wilson B., Gao H. M., Lu R. B., Hong J. S., Clozapine protects dopaminergic neurons from inflammation-induced damage by inhibiting microglial overactivation. Journal of NeuroImmune Pharmacology 2012 7 1 187 201 10.1007/s11481-011-9309-0
178. Pandya C. D., Howell K. R., Pillai A., Antioxidants as potential therapeutics for neuropsychiatric disorders. Progress in Neuropsychopharmacology & Biological Psychiatry 2013 46 214 223 10.1016/j.pnpbp.2012.10.017
179. Dodd S., Maes M., Anderson G., Dean O. M., Moylan S., Berk M., Putative neuroprotective agents in neuropsychiatric disorders. Progress in Neuro-Psychopharmacology & Biological Psychiatry 2013 42 135 145 10.1016/j.pnpbp.2012.11.007
180. Grillo R. W., Ottoni G. L., Leke R., Souza D. O., Portela L. V., Lara D. R., Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. Journal of Psychiatric Research 2007 41 1-2 31 35 2-s2.0-33750735357 10.1016/j.jpsychires.2006.01.005 (Pubitemid 44708213)
181. Pedrini M., Chendo I., Grande I., Lobato M. I., Belmonte-de-Abreu P. S., Lersch C., Walz J., Kauer-Sant'Anna M., Kapczinski F., Gama C. S., Serum brain-derived neurotrophic factor and clozapine daily dose in patients with schizophrenia: a positive correlation. Neuroscience Letters 2011 491 3 207 210 2-s2.0-79951773515 10.1016/j.neulet.2011.01.039
182. Lim C.-M., Kim S.-W., Park J.-Y., Kim C., Yoon S. H., Lee J.-K., Fluoxetine affords robust neuroprotection in the postischemic brain via its anti-inflammatory effect. Journal of Neuroscience Research 2009 87 4 1037 1045 2-s2.0-63849303038 10.1002/jnr.21899
183. Wehner N. G., Skov M., Shopp G., Rocca M. S., Clarke J., Effects of natalizumab, an α 4 integrin inhibitor, on fertility in male and female guinea pigs. Birth Defects Research B 2009 86 2 108 116 2-s2.0-65549091168 10.1002/bdrb.20191